Delong Liu

发表

Distinct genetic alterations in small cell carcinoma from different anatomic sites

J. Fallon, M. Zhong, Xiaoyong Zheng, 2015, Experimental Hematology & Oncology.

Recent advances in myelodysplasia: update from 2011 ASH annual meeting

Delong Liu, 2012, Journal of Hematology & Oncology.

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a

Delong Liu, G. Wei, M. Rafiyath, 2012 .

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

Yue-hua Ma, Delong Liu, S. Cang, 2009, Journal of hematology & oncology.

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia

Delong Liu, Bo Yu, 2019, Biomarker Research.

CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.

K. Seiter, Delong Liu, P. Baskind, 2016, Leukemia research.

Evaluation of Temozolomide in Patients with Myelodysplastic Syndrome

R. Lerner, T. Ahmed, K. Seiter, 2004, Leukemia & lymphoma.

Novel strategies for immuno-oncology breakthroughs with cell therapy

Zihai Li, Lei Zheng, Delong Liu, 2021, Biomarker Research.

Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome

P. Galvin-Parton, T. Ahmed, K. Seiter, 2005, Leukemia & lymphoma.

Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells

Yamei Chen, P. Yang, Delong Liu, 2016, Oncotarget.

Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells

Yue-hua Ma, Delong Liu, S. Cang, 2014, Experimental Hematology & Oncology.

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

Shuhang Wang, Yongping Song, Delong Liu, 2016, Journal of Hematology & Oncology.

Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution

T. Ahmed, K. Seiter, E. Feldman, 2006, Leukemia & lymphoma.

Diagnosis and Treatment of CD 20 Negative B Cell Lymphomas

Delong Liu, 2019 .

Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report.

K. Seiter, Delong Liu, Jingjing Wu, 2016, Stem cell investigation.

SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma

Delong Liu, Roshni Narurkar, Mohammad Alkayem, 2016, Biomarker Research.

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Mingzhi Zhang, Delong Liu, Jingjing Wu, 2015, Journal of Hematology & Oncology.

Novel CD20 monoclonal antibodies for lymphoma therapy

Delong Liu, S. Cang, Nikhil Mukhi, 2012, Journal of Hematology & Oncology.

Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis

K. Seiter, Delong Liu, Sivamurthy Kyathari, 2008, Leukemia & lymphoma.

Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate.

T. Ahmed, K. Seiter, Delong Liu, 2004, Leukemia research.

Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia

Delong Liu, G. Wei, S. Rafiyath, 2013 .

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia

Delong Liu, S. Cang, 2008, Journal of hematology & oncology.

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy

Ting Yang, Delong Liu, S. Cang, 2009, Hematology Reviews.

Ibrutinib and novel BTK inhibitors in clinical development

Yamei Chen, Yongping Song, Delong Liu, 2013, Journal of Hematology & Oncology.

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

Mingzhi Zhang, Delong Liu, Jingjing Wu, 2016, Oncotarget.

Second-generation inhibitors of Bruton tyrosine kinase

Delong Liu, Jingjing Wu, Christina Liu, 2016, Journal of Hematology & Oncology.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Delong Liu, G. Wei, S. Rafiyath, 2010, Journal of hematology & oncology.

Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors

K. Seiter, Delong Liu, Nasir Ahmed, 2008, Drug design, development and therapy.

A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2006 .

K. Seiter, Delong Liu, J. Bilaniuk, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Delong Liu, Jiangning Zhao, Quanyi Lu, 2012, Cancer Cell International.

Babesiosis-associated immune thrombocytopenia.

A. Agarwal, Delong Liu, J. Nelson, 2017, Stem cell investigation.

Ibrutinib for B cell malignancies

Yamei Chen, George Dous, Delong Liu, 2014, Experimental Hematology & Oncology.

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

R. Larson, A. Yang, E. Wang, 2012, Journal of Hematology & Oncology.

t(8;14;18): A 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia

T. Ahmed, K. Seiter, Y. Lai, 2007, Molecular Cancer.

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

R. Larson, J. Franklin, L. Dreisbach, 2009 .

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Yue-hua Ma, Delong Liu, Xiongpeng Zhu, 2010, Journal of hematology & oncology.

Recent advances on blinatumomab for acute lymphoblastic leukemia

Yongping Song, Delong Liu, Juanjuan Zhao, 2019, Experimental Hematology & Oncology.

High-Dose Cytarabine-Mitoxantrone Versus Hyper-CVAD in Adult Acute Lymphoblastic Leukemia and Burkitt's Lymphoma: A Single Center Experience of Two Induction Regimens

Delong Liu, Gurpreet Lamba, Abhishek Marballi, 2013 .

High-Dose Cytarabine-Mitoxantrone Versus Hyper-CVAD in Adult Acute Lymphoblastic Leukemia and Burkitt’s Lymphoma: A Single Center Experience of Two Induction Regimens

K. Seiter, Q. Shi, Delong Liu, 2009 .

Novel antidotes for target specific oral anticoagulants

Delong Liu, Arundhati Das, 2015, Experimental Hematology & Oncology.

A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.

Delong Liu, H. Islam, C. Puccio, 2016, Stem cell investigation.

Megakaryocytes regulate the quiescence of hematopoietic stem cells through PF4: 2013 ASH meeting highlights.

Yamei Chen, Delong Liu, 2014, Stem cell investigation.

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Mingzhi Zhang, Delong Liu, Jingjing Wu, 2016, Journal of Hematology & Oncology.

PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma.

T. Ahmed, K. Seiter, Delong Liu, 2005, Leukemia research.

Novel ALK inhibitors in clinical use and development

V. Mittal, Delong Liu, M. Furqan, 2015, Journal of Hematology & Oncology.

Syk inhibitors in clinical development for hematological malignancies

Delong Liu, Aleksandra Mamorska-Dyga, A. Mamorska-Dyga, 2017, Journal of Hematology & Oncology.

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

He Huang, Z. Cai, Delong Liu, 2011, Journal of hematology & oncology.

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab

S. Chugh, Delong Liu, S. Yandrapalli, 2017, Experimental Hematology & Oncology.

Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine

K. Seiter, Delong Liu, P. Caron, 2007, Leukemia & lymphoma.

Extramedullary hematopoiesis presented as cytopenia and massive paraspinal masses leading to cord compression in a patient with hereditary persistence of fetal hemoglobin

Delong Liu, H. Islam, K. Kolandaivel, 2016, Biomarker Research.

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.

Shuhang Wang, Yongping Song, Delong Liu, 2017, Cancer letters.

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Delong Liu, Yue-hua Ma, Delong Liu, 2010, Journal of hematology & oncology.

Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

O. Frankfurt, S. Kambhampati, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.

Qin-jun Zhao, Z. Han, Xin Wang, 2006, Haematologica.

Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment

F. Gao, Yongping Song, Zhongxing Jiang, 2021, Biomarker Research.

Engineering switchable and programmable universal CARs for CAR T therapy

Yongping Song, Juanjuan Zhao, Delong Liu, 2019, Journal of Hematology & Oncology.

Universal CARs, universal T cells, and universal CAR T cells

Juanjuan Zhao, Quande Lin, Yongping Song, 2018, Journal of Hematology & Oncology.

Combination strategies to maximize the benefits of cancer immunotherapy

Zihai Li, Lei Zheng, Delong Liu, 2021, Journal of Hematology & Oncology.

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Yongping Song, Delong Liu, Juanjuan Zhao, 2019, Journal of Hematology & Oncology.

Clinical Trials of CART Cells in China

Y. Song, B. Liu, Delong Liu, 2019 .

Clinical trials of CAR-T cells in China

Yongping Song, Delong Liu, Bingshan Liu, 2017, Journal of Hematology & Oncology.

Response but severe toxicity with low dose decitabine in a Werner’s syndrome patient with acute myeloid leukemia and t(9;19)(p13;p13)

K. Seiter, Delong Liu, E. Lulaj, 2016 .

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

Delong Liu, Byung Lee, Delong Liu, 2012, Experimental Hematology & Oncology.

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

Kaushal Parikh, A. Sekhri, Delong Liu, 2014, Journal of Hematology & Oncology.

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Yongping Song, Delong Liu, M. Furqan, 2013, Journal of Hematology & Oncology.

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application

Delong Liu, Byung Lee, Delong Liu, 2013, Biomarker Research.

STAT inhibitors for cancer therapy

Yamei Chen, V. Mittal, Delong Liu, 2013, Journal of Hematology & Oncology.

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy

Delong Liu, G. Wei, Kemeng Wang, 2012, Experimental Hematology & Oncology.

Recent updates on CAR T clinical trials for multiple myeloma

Yongping Song, Delong Liu, Q. Lin, 2019, Molecular Cancer.

MEK and the inhibitors: from bench to bedside

Delong Liu, Delong Liu, Muhammad Furqan, 2013, Journal of Hematology & Oncology.

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Yongping Song, Delong Liu, S. Cang, 2015, Journal of Hematology & Oncology.

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

Delong Liu, Bo Yu, 2019, Journal of Hematology & Oncology.

Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.

A. Sekhri, T. Ahmed, K. Seiter, 2009, Leukemia research.

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Zihai Li, M. Rubinstein, Delong Liu, 2018, Journal of Hematology & Oncology.

Clinical applications of PD-L1 bioassays for cancer immunotherapy

Shuhang Wang, W. Bindeman, Delong Liu, 2017, Journal of Hematology & Oncology.

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Shuhang Wang, Feifei Yan, Yongping Song, 2016, Frontiers of Medicine.

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Shuhang Wang, Delong Liu, S. Cang, 2016, Journal of Hematology & Oncology.

Diagnosis and treatment of CD20 negative B cell lymphomas

Delong Liu, T. Katchi, 2017, Biomarker Research.

Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG

K. Seiter, Delong Liu, K. Linder, 2016, Experimental Hematology & Oncology.

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Mingzhi Zhang, Delong Liu, Jingjing Wu, 2015, Journal of Hematology & Oncology.

Selective inhibitors of nuclear export (SINE) in hematological malignancies

Kaushal Parikh, Delong Liu, G. Wei, 2015, Experimental Hematology & Oncology.

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

Yongping Song, Delong Liu, Juanjuan Zhao, 2019, Biomarker Research.

Current management and prognostic features for gastrointestinal stromal tumor (GIST)

Delong Liu, S. Ambrale, Byung Lee, 2012, Experimental Hematology & Oncology.

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Delong Liu, Amandeep Aujla, Ravijot Aujla, 2019, Biomarker Research.

Publish, not perish: Introducing Experimental Hematology & Oncology

C. Hsueh, Zihai Li, Delong Liu, 2012, Experimental Hematology & Oncology.

Current management and novel agents for malignant melanoma

Delong Liu, Byung Lee, N. Mukhi, 2012, Journal of Hematology & Oncology.

1-1-2017 PD-1 , PD-L 1 ( B 7-H 1 ) and Tumor-site Immune Modulation Therapy : the Historical Perspective

R. Yuan, Zihai Li, Delong Liu, 2019 .

Novel agents for advanced pancreatic cancer

Delong Liu, M. Furqan, S. Cang, 2015, Oncotarget.

Autoimmune hemolytic anemia associated with babesiosis

Delong Liu, J. Nelson, Aleksandra Mamorska-Dyga, 2017, Biomarker Research.

t(3;9;22) 3-Way Chromosome Translocation in Chronic Myeloid Leukemia is Associated with Poor Prognosis

K. Seiter, Delong Liu, S. Cang, 2009, Cancer investigation.

Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Delong Liu, S. Ambrale, Byung Lee, 2012, Journal of Hematology & Oncology.

Intravenous Bolus Topotecan in Patients with Myelodysplastic Syndrome

T. Ahmed, K. Seiter, E. Feldman, 2001, Leukemia & lymphoma.

Cancer biomarkers for targeted therapy

Delong Liu, 2019, Biomarker Research.

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

Delong Liu, 2019, Journal of Hematology & Oncology.

Prospective Evaluation of 2009 H1N1 Influenza A in Patients Admitted with Fever to an Oncology Unit

R. Nadelman, K. Seiter, Q. Shi, 2011, Infection Control & Hospital Epidemiology.

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Zihai Li, Delong Liu, C. Pan, 2020, Journal of Hematology & Oncology.

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

R. Yuan, Zihai Li, Delong Liu, 2017, Journal of Hematology & Oncology.

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Delong Liu, W. Ding, Hong Zheng, 2021, Journal of Hematology & Oncology.

New developments in Hematology and Oncology in 2011

Delong Liu, Qi-fa Liu, 2012 .

Cytokine release syndrome: grading, modeling, and new therapy

Delong Liu, Juanjuan Zhao, 2018, Journal of Hematology & Oncology.

Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report

Yongping Song, Delong Liu, Wahib Zafar, 2018, Frontiers of Medicine.

B-Raf and the inhibitors: from bench to bedside

M. Karsy, J. Zhuge, Delong Liu, 2013, Journal of Hematology & Oncology.

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Ting Yang, Yongping Song, Delong Liu, 2019, Journal of Hematology & Oncology.

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Yamei Chen, A. Gass, K. Seiter, 2014, Frontiers of Medicine.

Frontline therapies for untreated chronic lymphoid leukemia

Delong Liu, Juanjuan Zhao, 2019, Experimental Hematology & Oncology.

Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support.

K. Seiter, Delong Liu, M. Stiefel, 2016, Stem cell investigation.

Acute promyelocytic leukemia with tetraploid karyotype: first report in the Western hemisphere and update of previous reports.

K. Kojima, K. Seiter, O. Miura, 2011, Leukemia research.

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

Yongping Song, Delong Liu, Bingshan Liu, 2017, Journal of Hematology & Oncology.

Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials

Hong Wang, Delong Liu, Hong Wang, 2013, Biomarker Research.

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia

Delong Liu, Bo Yu, 2019, Biomarker Research.

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

Delong Liu, K. Linder, Chaitanya Iragavarapu, 2018, Biomarker Research.

BCMA-targeted immunotherapy for multiple myeloma

Delong Liu, Bo Yu, Tianbo Jiang, 2020, Journal of Hematology & Oncology.

Phase I study of temozolomide in relapsed/refractory acute leukemia.

T. Ahmed, K. Seiter, T. Loughran, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome

Delong Liu, K. Linder, Chaitanya Iragavarapu, 2017, Biomarker Research.

Increased Mortality Among Patients With Acute Leukemia Admitted on Weekends Compared to Weekdays

Delong Liu, S. Arora, M. Shah, 2017, Clinical lymphoma, myeloma & leukemia.

Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective

Shanti Patel, Delong Liu, S. Kaur, 2018, Journal of Hematology & Oncology.

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

Yongping Song, Delong Liu, Li-na Zhang, 2018, Journal of Hematology & Oncology.

CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function

T. Ahmed, Delong Liu, Keyur Thakar, 2014, Biomarker Research.

Second- and third-generation ALK inhibitors for non-small cell lung cancer

Delong Liu, Jingjing Wu, John Savooji, 2016, Journal of Hematology & Oncology.

Lineage switch from T-cell lymphoblastic leukemia/lymphoma to acute myeloid leukemia and back to T-cell lymphoblastic leukemia/lymphoma in a patient diagnosed during pregnancy.

K. Seiter, Delong Liu, H. Islam, 2019, Stem cell investigation.

Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways

Xianghua Lin, Delong Liu, Marietta Y. W. T. Lee, 2008, Journal of hematology & oncology.

Isolated factor V deficiency in a patient with elevated PT and aPTT during routine pre-operative laboratory screening.

Yamei Chen, Delong Liu, Keyur Thakar, 2014, Stem cell investigation.

Journal of hematology & oncology: A journal open to all

Delong Liu, 2008, Journal of hematology & oncology.

Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

J. Cortes, M. Chandy, G. Ossenkoppele, 2008 .

Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment

Yingmei Li, Yongping Song, Zhongxing Jiang, 2021, Biomarker research.

Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells

Yue-hua Ma, Delong Liu, S. Cang, 2016, Journal of Hematology & Oncology.

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

Delong Liu, K. Linder, Chaitanya Iragavarapu, 2018, Biomarker Research.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Delong Liu, G. Wei, S. Rafiyath, 2010, Journal of hematology & oncology.

MEK and the inhibitors: from bench to bedside

Delong Liu, M. Furqan, Akintunde Akinleye, 2013, Journal of Hematology & Oncology.

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Delong Liu, Amandeep Aujla, Ravijot Aujla, 2019, Biomarker Research.

Cancer biomarkers for targeted therapy

Delong Liu, 2019, Biomarker Research.

Recent updates on CAR T clinical trials for multiple myeloma

Yongping Song, Delong Liu, Q. Lin, 2019, Molecular Cancer.

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

Yongping Song, Delong Liu, Juanjuan Zhao, 2019, Biomarker Research.

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Zihai Li, M. Rubinstein, Delong Liu, 2018, Journal of Hematology & Oncology.

CD34(+) therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer.

K. Seiter, Delong Liu, H. Islam, 2016, Stem cell investigation.

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

Xiao-hui Zhang, Delong Liu, Qiu-Sha Huang, 2023, Journal of Hematology & Oncology.

Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2007 .

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

S. Kambhampati, H. Kantarjian, T. Kadia, 2018, Blood.

Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy

T. Ahmed, K. Seiter, C. Sreekantaiah, 2001, Leukemia.